Company Reports Q1 Revenue of $122.9M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy NATR?
Reports Q1 revenue $122.9M vs. $113.2M last year. Sales growth was generated across all regions, led by North America, while gross profit margins increased driven by cost savings initiatives, market mix, and favorable foreign exchange. "We delivered a strong start to 2026, reflecting continued momentum across our key strategic initiatives," said CEO Ken Romanzi.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NATR
Wall Street analysts forecast NATR stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 24.550
Low
22.00
Averages
22.50
High
23.00
Current: 24.550
Low
22.00
Averages
22.50
High
23.00
About NATR
Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nature's Sunshine Reports Strong Q1 2026 Earnings with 9% Sales Growth
- Significant Sales Growth: Nature's Sunshine reported net sales of $122.9 million in Q1 2026, reflecting a 9% year-over-year increase, marking the strongest first quarter in the company's history, showcasing sustained growth momentum across all regions, particularly in North America.
- Digital Channel Success: Sales in North America reached $38.3 million, with the digital business growing by 42% and new digital customers increasing by 60%, indicating the company's successful digital transformation efforts that enhance customer loyalty and market competitiveness.
- Margin Improvement: The gross margin increased by 116 basis points to 73.2% in Q1, reflecting improvements in cost control and operational efficiency, with expectations for gross margins to average around 73% in 2026, laying a solid foundation for future profitability.
- Strategic Expansion Plans: The company plans to enter the German market and has set long-term goals of achieving $1 billion in sales and a 15% EBITDA margin, demonstrating its ambition for global market expansion and digital investment.
See More
NATURE'S SUNSHINE PROJECTS FY NET SALES BETWEEN USD 500-515 MILLION
- Sales Overview: Nature's Sunshine reported sales between USD 500 million and USD 515 million for the fiscal year.
- Market Performance: The company's sales figures indicate a strong performance in the health and wellness market.
See More
Analysis of Three Stocks Capturing Wall Street's Attention
- Nature's Sunshine Underperformance: Despite Wall Street's consensus price target of $33 for Nature's Sunshine (NATR), implying a 25.6% return, its annual growth of only 4.4% over the past three years indicates a lack of competitive strength in the consumer staples sector.
- First Advantage Stagnation: With a consensus price target of $15 and a 24.2% implied return, First Advantage (FA) has seen flat earnings per share over the last four years, and its free cash flow margin has dropped by 8.6 percentage points, suggesting increased capital intensity amid rising competition.
- ResMed Growth Potential: ResMed (RMD) boasts a consensus price target of $292.33, reflecting a 30.1% implied return, with a consistent average growth rate of 9% over the past two years and a 14.2% annual increase in earnings per share, showcasing robust profitability.
- Caution for Investors: While Wall Street's bullish forecasts for these stocks are compelling, analysts' optimism may overlook significant risks, prompting investors to carefully assess each company's fundamentals and market conditions before making investment decisions.
See More
Nature's Sunshine Shares Surge 84.3% Amid Mixed Outlook
- Stock Performance: Nature's Sunshine shares have surged 84.3% over the past six months, reaching $26.36 per share; however, analysts express caution regarding the sustainability of this rally amid mixed future prospects.
- Long-Term Revenue Growth: Despite a solid quarterly performance, the company has only achieved a 4.4% compounded annual growth rate over the last three years, significantly below the consumer staples sector benchmark, which may undermine investor confidence in its growth potential.
- Limited Distribution Channels: With $480.1 million in revenue over the past 12 months, Nature's Sunshine, as a small consumer staples company, faces disadvantages due to fewer distribution channels, limiting its competitive edge against larger rivals and constraining market potential.
- Weak Operating Margin: The company's average operating margin of 4.8% over the past two years is relatively low for the consumer staples sector, indicating a suboptimal cost structure that could pose challenges to future profitability.
See More
Nature's Sunshine Products Reports Strong Q4 2025 Earnings and Growth Vision
- Significant Sales Growth: Nature's Sunshine achieved net sales of $123.8 million in Q4 2025, representing a 5% year-over-year increase, marking the company's second-largest quarterly performance in history and demonstrating strong global market presence.
- Improved Profitability: The adjusted EBITDA for Q4 reached $11.9 million, up 16% year-over-year, while GAAP net income was $4.1 million, indicating a continuous improvement in profitability that enhances investor confidence.
- Positive Future Outlook: The company expects net sales for 2026 to range between $500 million and $515 million, reflecting a year-over-year growth of 4% to 7%, with plans for strategic investments in technology infrastructure and customer acquisition to support long-term growth.
- Accelerated Digital Transformation: Digital business revenue surged by 47% year-over-year, with digital subscriptions accounting for 47% of total revenue, indicating significant progress in the company's digital transformation efforts, which are expected to further drive future sales growth.
See More
Nature's Sunshine Q4 Earnings Beat Expectations with Strong Revenue Growth
- Strong Earnings Report: Nature's Sunshine reported a Q4 non-GAAP EPS of $0.30, beating expectations by $0.12, which highlights a significant improvement in profitability and boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $123.8 million, reflecting a 4.7% year-over-year increase and surpassing market expectations by $2.3 million, indicating robust demand for its products and solid market performance.
- Future Outlook: Nature's Sunshine anticipates full-year 2026 net sales to range between $500 million and $515 million, with adjusted EBITDA expected to be between $50 million and $54 million, demonstrating confidence in future growth prospects.
- Market Reaction: Following the earnings release, market interest in Nature's Sunshine has increased, with analysts expressing optimism about its future performance, potentially attracting more investor attention.
See More
Nature's Sunshine Reports Strong Q1 2026 Earnings with 9% Sales Growth
- Significant Sales Growth: Nature's Sunshine reported net sales of $122.9 million in Q1 2026, reflecting a 9% year-over-year increase, marking the strongest first quarter in the company's history, showcasing sustained growth momentum across all regions, particularly in North America.
- Digital Channel Success: Sales in North America reached $38.3 million, with the digital business growing by 42% and new digital customers increasing by 60%, indicating the company's successful digital transformation efforts that enhance customer loyalty and market competitiveness.
- Margin Improvement: The gross margin increased by 116 basis points to 73.2% in Q1, reflecting improvements in cost control and operational efficiency, with expectations for gross margins to average around 73% in 2026, laying a solid foundation for future profitability.
- Strategic Expansion Plans: The company plans to enter the German market and has set long-term goals of achieving $1 billion in sales and a 15% EBITDA margin, demonstrating its ambition for global market expansion and digital investment.
See More
NATURE'S SUNSHINE PROJECTS FY NET SALES BETWEEN USD 500-515 MILLION
- Sales Overview: Nature's Sunshine reported sales between USD 500 million and USD 515 million for the fiscal year.
- Market Performance: The company's sales figures indicate a strong performance in the health and wellness market.
See More
Analysis of Three Stocks Capturing Wall Street's Attention
- Nature's Sunshine Underperformance: Despite Wall Street's consensus price target of $33 for Nature's Sunshine (NATR), implying a 25.6% return, its annual growth of only 4.4% over the past three years indicates a lack of competitive strength in the consumer staples sector.
- First Advantage Stagnation: With a consensus price target of $15 and a 24.2% implied return, First Advantage (FA) has seen flat earnings per share over the last four years, and its free cash flow margin has dropped by 8.6 percentage points, suggesting increased capital intensity amid rising competition.
- ResMed Growth Potential: ResMed (RMD) boasts a consensus price target of $292.33, reflecting a 30.1% implied return, with a consistent average growth rate of 9% over the past two years and a 14.2% annual increase in earnings per share, showcasing robust profitability.
- Caution for Investors: While Wall Street's bullish forecasts for these stocks are compelling, analysts' optimism may overlook significant risks, prompting investors to carefully assess each company's fundamentals and market conditions before making investment decisions.
See More
Nature's Sunshine Shares Surge 84.3% Amid Mixed Outlook
- Stock Performance: Nature's Sunshine shares have surged 84.3% over the past six months, reaching $26.36 per share; however, analysts express caution regarding the sustainability of this rally amid mixed future prospects.
- Long-Term Revenue Growth: Despite a solid quarterly performance, the company has only achieved a 4.4% compounded annual growth rate over the last three years, significantly below the consumer staples sector benchmark, which may undermine investor confidence in its growth potential.
- Limited Distribution Channels: With $480.1 million in revenue over the past 12 months, Nature's Sunshine, as a small consumer staples company, faces disadvantages due to fewer distribution channels, limiting its competitive edge against larger rivals and constraining market potential.
- Weak Operating Margin: The company's average operating margin of 4.8% over the past two years is relatively low for the consumer staples sector, indicating a suboptimal cost structure that could pose challenges to future profitability.
See More
Nature's Sunshine Products Reports Strong Q4 2025 Earnings and Growth Vision
- Significant Sales Growth: Nature's Sunshine achieved net sales of $123.8 million in Q4 2025, representing a 5% year-over-year increase, marking the company's second-largest quarterly performance in history and demonstrating strong global market presence.
- Improved Profitability: The adjusted EBITDA for Q4 reached $11.9 million, up 16% year-over-year, while GAAP net income was $4.1 million, indicating a continuous improvement in profitability that enhances investor confidence.
- Positive Future Outlook: The company expects net sales for 2026 to range between $500 million and $515 million, reflecting a year-over-year growth of 4% to 7%, with plans for strategic investments in technology infrastructure and customer acquisition to support long-term growth.
- Accelerated Digital Transformation: Digital business revenue surged by 47% year-over-year, with digital subscriptions accounting for 47% of total revenue, indicating significant progress in the company's digital transformation efforts, which are expected to further drive future sales growth.
See More
Nature's Sunshine Q4 Earnings Beat Expectations with Strong Revenue Growth
- Strong Earnings Report: Nature's Sunshine reported a Q4 non-GAAP EPS of $0.30, beating expectations by $0.12, which highlights a significant improvement in profitability and boosts investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $123.8 million, reflecting a 4.7% year-over-year increase and surpassing market expectations by $2.3 million, indicating robust demand for its products and solid market performance.
- Future Outlook: Nature's Sunshine anticipates full-year 2026 net sales to range between $500 million and $515 million, with adjusted EBITDA expected to be between $50 million and $54 million, demonstrating confidence in future growth prospects.
- Market Reaction: Following the earnings release, market interest in Nature's Sunshine has increased, with analysts expressing optimism about its future performance, potentially attracting more investor attention.
See More
